Adding the PARP inhibitor veliparib to a standard chemotherapy agent improves overall response rates in patients with small cell lung cancer (SCLC). The findings from a randomized, Phase II trial led by a research team at The University of Texas MD Anderson Cancer Center is published in iJournal of Clinical Oncology/i.
The research team also identified a select group of patients - those whose tumors expressed SLFN11-- who also saw a progression-free survival (PFS) and overall survival (OS) ...
Adding the PARP inhibitor veliparib to a standard chemotherapy agent improves overall response rates in patients with small cell lung cancer (SCLC). The findings from a randomized, Phase II trial led by a research team at The University of Texas MD Anderson Cancer Center is published in iJournal of Clinical Oncology/i.
The research team also identified a select group of patients - those whose tumors expressed SLFN11-- who also saw a progression-free survival (PFS) and overall survival (OS) ...